# US 11,026,897 B2 · Composition of curcumagalactomannoside and hops extract > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,026,897 B2 - Document ID: US11026897B2 - Status: Granted - Kind: B2 - Application number: 16/536,449 - Filed: 2019-08-09 - Published: 2020-02-13 - Granted: 2021-06-08 - Earliest claimed: 2018-08-10 - Assignees: Metagenics, Inc. - Applicants: Metagenics, Inc. - Inventors: Nikhat Contractor; Jennifer Joan Ryan - Web page: https://patentgrep.com/patent/US11026897B2 ## CPC - A61K 31/12: Ketones - A61K 31/085: having an ether linkage to aromatic ring nuclear carbon - A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) - A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)} - A61K 31/366: having six-membered rings, e.g. delta-lactones - A61K 31/519: ortho- or peri-condensed with heterocyclic rings - A61K 31/714: Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12 - A61K 31/736: Glucomannans or galactomannans, e.g. locust bean gum, guar gum - A61K 36/3486: {Humulus} - A61K 36/53: Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender - A61K 36/906: Zingiberaceae (Ginger family) - A61K 36/9066: Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract A composition for treatment of inflammation in a mammal is provided. The mammal has a neutrophil to lymphocyte ratio (NLR). The composition includes a curcumagalactomannoside and a hops extract. The curcumagalactomannoside and the hops extract cooperate to decrease the NLR of the mammal 12 weeks after ingestion of the composition. A method of treatment of inflammation in a mammal is also provided. The method includes obtaining a parameter of the mammal. The method further includes dosing the composition based on the parameter. The method further includes administering the composition to the mammal. ## Claims ### Claim 1 A composition for treatment of inflammation in a mammal, the mammal having a neutrophil to lymphocyte ratio (NLR), the composition comprising: a curcumagalactomannoside; and a hops extract; wherein the curcumagalactomannoside and the hops extract cooperate to decrease the NLR of the mammal 12 weeks after ingestion of the composition. ### Claim 2 (depends on 1) The composition of claim 1, wherein the curcumagalactomannoside is derived from a curcuminoid and a galactomannan. ### Claim 3 (depends on 2) The composition of claim 2, wherein the curcuminoid is present in the curcumagalactomannoside in an amount of from about 20 wt. % to about 60 wt. % based on a total weight of the curcumagalactomannoside. ### Claim 4 (depends on 1) The composition of claim 1, wherein the curcumagalactomannoside is present in the composition in an amount of from about 0.01 wt. % to about 10 wt. % based on a total weight of the composition. ### Claim 5 (depends on 1) The composition of claim 1, wherein the hops extract comprises xanthohumol. ### Claim 6 (depends on 1) The composition of claim 1, comprising a protein-containing matrix, the protein-containing matrix comprising the hops extract. ### Claim 7 (depends on 6) The composition of claim 6, wherein the hops extract is present in the protein-containing matrix in an amount of from about 1 wt. % to about 95 wt. % based on a total weight of the protein-containing matrix. ### Claim 8 (depends on 1) The composition of claim 1, wherein the hops extract is present in the composition in an amount of from about 0.01 wt. % to about 10 wt. % based on a total weight of the composition. ### Claim 9 (depends on 1) The composition of claim 1, further comprising a ginger root extract. ### Claim 10 (depends on 9) The composition of claim 9, wherein the ginger root extract comprises a pungent compound in an amount of from about 0.1 wt. % to about 20 wt. % based on a total weight of the ginger root extract. ### Claim 11 (depends on 1) The composition of claim 1, further comprising aquercetin, rosemary extract, folate, vitamin B-12, or combinations thereof. ### Claim 12 (depends on 1) The composition of claim 1, further comprising an amino acid, a peptide, a protein, a lipid, a vitamin, a carbohydrate, a nucleic acid, a mineral, an anabolic nutrient, an antioxidant, a probiotic bacterial strain, a lipotropic agent, a flavoring agent, a dye, a flow modifier, a preservative, a filler, a binder, a dispersing agent, a human milk oligosaccharide, isomalto-oligosaccharide, a fiber, or combinations thereof. ### Claim 13 (depends on 12) The composition of claim 12, wherein the amino acid is present and the amino acid is selected from the group consisting of L-lysine, L-leucine, L-glutamine, L-valine, L-isoleucine, and combinations thereof. ### Claim 14 A composition for treatment of inflammation in a mammal, the mammal having a neutrophil to lymphocyte ratio (NLR), the composition consisting essentially of: curcumagalactomannoside; a hops extract; a ginger root extract; a protein-containing matrix; a rosemary leaf extract; folate; vitamin B-12; and quercetin; wherein at least the curcumagalactomannoside and hops extract cooperate to decrease the NLR of the mammal 12 weeks after ingestion of the composition. ### Claim 15 A composition for treatment of inflammation in a mammal, the mammal having a neutrophil to lymphocyte ratio (NLR), the composition comprising: a curcumagalactomannoside; and a protein-containing matrix; wherein the protein-containing matrix comprises a hops extract; and wherein the curcumagalactomannoside and the hops extract cooperate to decrease the NLR of the mammal 12 weeks after ingestion of the composition; optionally, wherein the hops extract is present in the protein-containing matrix in an amount of from about 1 wt. % to about 95 wt. % based on a total weight of the protein-containing matrix. ### Claim 16 (depends on 15) The composition of claim 15, wherein the curcumagalactomannoside is derived from a curcuminoid and a galactomannan, optionally wherein the curcuminoid is present in the curcumagalactomannoside in an amount of from about 20 wt. % to about 60 wt. % based on a total weight of the curcumagalactomannoside. ### Claim 17 (depends on 15) The composition according to claim 15, wherein the hops extract is present in the protein-containing matrix in an amount of from about 1 wt. % to about 95 wt. % based on a total weight of the protein-containing matrix. ### Claim 18 (depends on 17) The composition of claim 17, wherein: i) the curcumagalactomannoside is present in the composition in an amount of from about 0.01 wt. % to about 10 wt. % based on a total weight of the composition; and ii) the hops extract is present in the composition in an amount of from about 0.01 wt. % to about 10 wt. % based on a total weight of the composition.